Phase Ib Dose Escalation And Cohort Expansion Study Of The Novel Myeloid Differentiating Agent Mtl-Cebpa In Combination With Sorafenib In Patients With Advanced Hepatocellular Carcinoma (Hcc).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要